Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.98+0.20 (+0.92%)
Close on Nov 12, 2026Market cap $2.08BP/E –Yield –
Replimune operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Replimune's operating cash flow for the twelve months ending Sep 30, 2026 was -$245.55M. For fiscal 2026 it was -$280.34M. The highest annual figure on record is -$7.08M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$280.34M | – |
| FY2025 | Mar 31, 2025 | -$192.25M | – |
| FY2024 | Mar 31, 2024 | -$185.47M | – |
| FY2023 | Mar 31, 2023 | -$128.05M | – |
| FY2022 | Mar 31, 2022 | -$82.18M | – |
| FY2021 | Mar 31, 2021 | -$61.39M | – |
| FY2020 | Mar 31, 2020 | -$60.55M | – |
| FY2019 | Mar 31, 2019 | -$25.38M | – |
| FY2018 | Mar 31, 2018 | -$16.01M | – |
| FY2017 | Mar 31, 2017 | -$7.08M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | -$47.70M | – |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$75.73M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$56.16M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$65.96M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$81.21M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$77.02M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$53.73M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$50.71M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$38.64M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$49.17M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$46.17M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$47.12M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$43.59M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$48.59M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$32.80M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$28.59M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$33.21M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$33.46M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$22.56M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$18.35M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$22.96M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$18.31M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$16.13M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$12.99M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$17.18M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$15.09M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$11.26M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$15.74M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$19.97M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$13.58M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$6.03M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$6.10M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$6.38M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$6.86M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$4.23M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$2.70M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$3.59M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$5.49M | – |
See a number that looks wrong?